An experimental weight loss drug has enabled some obese individuals living with type 2 diabetes to shed up to a quarter of their body weight while maintaining control over blood sugar levels, a trial has revealed.
Eli Lilly’s retatrutide operates by imitating three separate hormones to manage appetite and blood sugar while accelerating metabolism. It differs from existing GLP-1 drugs that replicate only one or two hormones, though it has not yet received regulatory approval in the UK.
